Latest news with #Johnson & Johnson
Yahoo
4 days ago
- Business
- Yahoo
Carlsmed seeks up to $103M IPO haul to fuel spine surgery growth
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: Carlsmed has set the target range for its initial public offering, outlining plans to raise up to $103.3 million to support development and commercialization of its spine surgery platform. Carlsmed plans to offer 6.7 million shares of common stock at an expected range of $14 to $16 per share, as well as an underwriters' option to purchase more than 1 million shares. The company, which set the price range Tuesday, sells artificial intelligence-enabled software, custom implants and single-use instruments for spine surgeries. Cross-trial comparisons suggest the custom devices may improve alignment and reduce revisions compared to stock implants. Carlsmed's products compete with stock spine implants sold by companies including Medtronic, Johnson & Johnson and Globus Medical. The company is much smaller than its rivals but growing quickly, with sales increasing by almost 100% in 2024 and on track to rise again this year. Dive Insight: Carlsmed is developing its platform to address the limitations of traditional spine fusion procedures. The company has identified the lack of sufficient pre-operative planning, the fit of stock interbody implants and complicated surgical workflows as problems. Targeting a $13.4 billion addressable market, Carlsmed is working to address these issues to improve patient outcomes and cut healthcare costs. The resulting platform uses diagnostic imaging and AI-enabled algorithms to develop personalized digital surgical plans and design custom interbody implants for each patient. Carlsmed collects real-world, post-operative data to improve the planning process. Researchers have generated evidence of the effectiveness of the platform, including through a registry that is tracking real-world clinical outcomes. An interim analysis of 67 adult spinal deformity patients in the registry found the rate of revision surgery attributable to mechanical complications was 1.5% after a mean follow-up of 14.7 months, according to a federal securities filing. The one-year revision rate in another study of stock implants was 8.7%. Carlsmed reported revenue of $27.2 million last year, up almost 100% compared to 2023, and is on track to grow again in 2025. The company generated sales of around $22.2 million over the first half of 2025. Carlsmed plans to keep growing by adding users and increasing use by existing customers. The number of surgeons who have used the platform increased from 103 as of March 2024 to 199 as of June 2025. Carlsmed's IPO paperwork reveals some of the challenges the company is facing as it scales operations. The company's net loss increased last year, rising to $24.2 million, and its reliance on a limited number of contract manufacturing organizations has hurt margins. Delays in the approval of surgical plans or late changes in surgery dates can cause CMOs to charge expedite fees. The fees drove margins down in the second quarter. Carlsmed expects expedite fees to decrease over time as it tries to improve operational processes and procedural workflows used by surgeons. Carlsmed's filing to list on Nasdaq adds to the uptick in medtech IPO activity seen this year. IPO filings are still well down from the pandemic-era peak but, after years of limited activity, some analysts believe a backlog of companies is waiting for favorable conditions to list. The success or failure of companies such as Carlsmed could inform whether the IPO window opens or closes. Recommended Reading The medtech IPO window is finally open. Or is it? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
5 days ago
- Business
- Globe and Mail
3M boosts full-year profit forecast on smaller projected tariff hit
3M MMM-N on Friday raised its full-year profit forecast and projected a smaller tariff-related hit to its 2025 earnings, amid easing trade tensions between the U.S. and China, sending shares of the industrial giant up nearly 4% in premaket trading. The company now expects a full-year adjusted profit between $7.75 and $8 per share, compared with its previous estimate of $7.60 to $7.90. The forecast includes a net hit of 10 cents per share to its 2025 profit, compared with its earlier forecast of 20 cents to 40 cents. As some of the trade tensions show signs of easing, companies have begun to re-evaluate the potential financial fallout. Pharmaceutical major Johnson & Johnson has halved its projection for tariff-related costs to $200 million this year. China, which accounts for roughly 10% of 3M's global revenue, signed a comprehensive trade deal with the U.S. in June following months of trade tensions. Dividend-paying conglomerates with break-up potential that may reward investors Under the agreement, the U.S. has imposed a 10% baseline tariff on all Chinese imports, 20% on goods associated with President Donald Trump's accusation that China had not done enough to stem the flow of fentanyl, and kept the existing 25% tariffs from his first term. In April, 3M had estimated an $850 million potential annualized impact from tariffs before exemptions, with $675 million tied to U.S. and China tariffs. The Scotch tape maker reported second-quarter adjusted profit of $2.16 per share compared with Wall Street estimates of $2.01, according to data compiled by LSEG. Adjusted operating income margin in the quarter stood at 24.5%, up 290 basis points from a year earlier, as the company turned its focus away from legal liabilities and supply-chain issues, and toward developing new products. Total revenue for quarter came in at $6.16 billion. Analysts, on average, were expecting $6.11 billion in revenue.
Reuters
5 days ago
- Business
- Reuters
3M sees smaller tariff hit on 2025 profit amid easing US-China trade tensions
July 18 (Reuters) - 3M (MMM.N), opens new tab on Friday raised its full-year profit forecast and projected a smaller tariff-related hit to its 2025 earnings, amid easing trade tensions between the U.S. and China, sending shares of the industrial giant up nearly 4% in premaket trading. The company now expects a full-year adjusted profit between $7.75 and $8 per share, compared with its previous estimate of $7.60 to $7.90. The forecast includes a net hit of 10 cents per share to its 2025 profit, compared with its earlier forecast of 20 cents to 40 cents. As some of the trade tensions show signs of easing, companies have begun to reevaluate the potential financial fallout. Pharmaceutical major Johnson & Johnson (JNJ.N), opens new tab has halved its projection for tariff-related costs to $200 million this year. China, which accounts for roughly 10% of 3M's global revenue, signed a comprehensive trade deal with the U.S. in June following months of trade tensions. Under the agreement, the U.S. has imposed a 10% baseline tariff on all Chinese imports, 20% on goods associated with President Donald Trump's accusation that China had not done enough to stem the flow of fentanyl, and kept the existing 25% tariffs from his first term. In April, 3M had estimated an $850 million potential annualized impact from tariffs before exemptions, with $675 million tied to U.S. and China tariffs. The Scotch tape maker reported second-quarter adjusted profit of $2.16 per share compared with Wall Street estimates of $2.01, according to data compiled by LSEG. Adjusted operating income margin in the quarter stood at 24.5%, up 290 basis points from a year earlier, as the company turned its focus away from legal liabilities and supply-chain issues, and toward developing new products. Total revenue for quarter came in at $6.16 billion. Analysts, on average, were expecting $6.11 billion in revenue.
Globe and Mail
7 days ago
- Business
- Globe and Mail
3 Top Dividend Stocks Yielding More Than 3% That You Shouldn't Hesitate to Buy Right Now
Key Points ExxonMobil has the best dividend growth track record in the oil industry. Johnson & Johnson has increased its dividend for over 60 straight years. Essex Property Trust has delivered over three decades of dividend increases. With the S&P 500 back in rally mode, the dividend yield on the broad market index is falling. It was recently down to around 1.2%, which is approaching its record low last hit a quarter-century ago. It won't surprise you, then, that the dividend yield on many stocks isn't very appealing these days. However, there are still some attractive options out there for yield-seeking investors. ExxonMobil (NYSE: XOM), Essex Property Trust (NYSE: ESS), and Johnson & Johnson (NYSE: JNJ) all currently have dividend yields of more than 3%. With top-notch track records of paying dividends, income investors shouldn't hesitate to buy their shares right now. The best in the oil patch by far ExxonMobil built its business to withstand the ups and downs of the oil patch better than any of its peers. Its dividend history is a major testament to its resilience. The oil giant has increased its payout for 42 straight years. That not only leads the oil patch but is also a claim that only 4% of companies in the entire S&P 500 can make. Two factors have helped fuel Exxon's durable and growing dividend over the decades. First, it has an integrated business model built around advantaged assets -- i.e., low-cost, high-margin assets -- that allows it to generate more resilient cash flows than most of its peers do. On top of that, Exxon has a fortress balance sheet, with the lowest leverage ratio among its peer group. That gives it the financial flexibility to borrow money during periods of lower oil prices to continue funding its growth, which it repays as prices improve. Exxon should have plenty of fuel to continue increasing its dividend in the future. Its 2030 plan aims to boost its earnings by $20 billion and its cash flow by $30 billion. The company expects to deliver that growth by investing in expanding its advantaged assets and continuing to strip out structural costs. That earnings growth should enable Exxon to continue increasing its high-yielding dividend in the coming years. A healthy dividend stock Johnson & Johnson is a financial fortress. The healthcare behemoth has a pristine AAA credit rating, which is higher than that of the U.S. government. The company ended the first quarter with only $13.5 billion of net debt -- $52.3 billion of debt against $38.8 billion of cash and securities. That's a paltry amount for a company with a $380 billion market cap that produced about $20 billion in free cash flow last year, which easily covered its $11.8 billion dividend outlay. The company's strong financial position has helped support its ability to steadily increase its dividend. Johnson & Johnson has raised its dividend for 63 straight years. That qualifies it as an elite Dividend King, a company with 50 or more years of increasing its dividends. Johnson & Johnson's financial strength also enables it to invest heavily in growing its business. It spent $17 billion on research and development last year, as it remained one of the top research-and-development investors across all industries. The company also secured more than $30 billion of merger-and-acquisition deals last year. These investments position Johnson & Johnson to grow its earnings so that it can continue increasing its 3.3%-yielding dividend payment. A top-tier landlord Essex Property Trust is one of the country's largest apartment owners. The real estate investment trust (REIT) focuses solely on West Coast markets including Los Angeles, San Diego, San Francisco, and Seattle. Its properties benefit from the durable and growing demand for rental housing in those strong housing markets. The REIT has increased its dividend for 31 straight years, which is one of the longest growth streaks in the sector. Essex Property Trust has increased its payout by a cumulative 516% since its initial public offering in 1994. Its dividend currently yields 3.6%. Essex Property Trust is in an excellent position to continue increasing its dividend. Housing demand along the West Coast remains strong, which keeps occupancy levels high and rents rising. Meanwhile, the REIT has a strong investment-grade balance sheet, giving it ample financial flexibility to continue expanding its portfolio. The company will acquire operating properties, fund development projects, invest capital to redevelop existing assets, and provide loans to developers that often come with an option to buy the completed project. These investments complement rent growth, enhancing the REIT's ability to continue increasing its dividend. High-quality, high-yielding dividend stocks ExxonMobil, Johnson & Johnson, and Essex Property Trust have exceptional records of paying dividends. With yields currently above 3% and more growth likely, they're dividend stocks that you can buy without hesitation right now. Should you invest $1,000 in ExxonMobil right now? Before you buy stock in ExxonMobil, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and ExxonMobil wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $679,653!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,046,308!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
Yahoo
7 days ago
- Business
- Yahoo
Johnson & Johnson Lifts 2025 Outlook as Second-Quarter Results Top Street Views
Johnson & Johnson (JNJ) raised its full-year outlook on Wednesday as the healthcare products conglom
